Myelofibrosis Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
I
Recruiting
  • Myelofibrosis
  • +3 more
  • Anchorage, Alaska
  • +155 more
2022-04-06
Apr 6, 2022
C
Recruiting
  • Myelofibrosis
  • +3 more
  • Birmingham, Alabama
  • +92 more
2022-04-04
Apr 4, 2022
N
Completed
  • Chronic Myelogenous Leukemia
  • +9 more
  • Atlanta, Georgia
    Northside Hospital
2022-04-04
Apr 4, 2022
S
Recruiting
  • Myelofibrosis
  • Gainesville, Florida
  • +10 more
2022-04-04
Apr 4, 2022
T
Recruiting
  • Acute Lymphoblastic Leukemia
  • +15 more
  • Hematopoietic Cell Transplantation
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
2022-04-01
Apr 1, 2022
M
Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +10 more
  • Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-30
Mar 30, 2022
I
Completed
  • Myelofibrosis
  • +3 more
  • Ann Arbor, Michigan
  • +4 more
2022-03-28
Mar 28, 2022
S
Recruiting
  • Myelofibrosis
  • Antwerpen, Belgium
  • +11 more
2022-03-21
Mar 21, 2022
T
Recruiting
  • Myelofibrosis
  • Aurora, Colorado
  • +63 more
2022-03-05
Mar 5, 2022
C
Recruiting
  • Myelofibrosis
  • Hematopoietic Stem Cell Transplant
  • Minneapolis, Minnesota
    Center for International Blood and Marrow Transplant Research
2022-03-17
Mar 17, 2022
R
Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +36 more
  • Buffalo, New York
    Roswell Park Cancer Institute
2022-03-17
Mar 17, 2022
C
Recruiting
  • Myelofibrosis
  • +13 more
  • Phoenix, Arizona
  • +54 more
2022-03-04
Mar 4, 2022
K
Recruiting
  • Myelofibrosis
  • KER-050 monotherapy
  • KER-050 in combination with ruxolitinib
  • Tweed Heads, New South Wales, Australia
  • +4 more
2022-03-02
Mar 2, 2022
S
Not yet recruiting
  • Myelofibrosis
  • Jaktinib Hydrochloride Tablet
  • (no location specified)
2022-03-03
Mar 3, 2022